The patent covers ferromagnetic semiconductor-based
methods, devices, and compositions. The technology
enables measurements of magnetic spins and enhanced
magnetic switching effects, which could play a key
role in development of future semiconductor devices
based on "spintronics."
Traditional semiconductor devices operate by storing
information as charge - an electron's state represents
0 or 1. In contrast, spintronics taps into the spin
of electrons to store or transmit information, which
enables next-generation devices for memory, disk storage,
magnetic sensors, and quantum computers to be smaller,
more powerful, and have longer lives than today's
products.
"This patent covers foundational technology
for what we believe will be the next-generation of
semiconductor devices," said R. Bruce Stewart,
President of Arrowhead. "This patent further
strengthens our diversified portfolio of patents in
the nanotechnology space. Arrowhead and its subsidiaries
now control 36 issued U.S. patents and have licensed
over 240 U.S. and international patents and patent
applications."
About Arrowhead Research Corporation
Arrowhead Research is a development-stage nanotechnology
company structured to bring together a diverse and
innovative mix of technologies, rights to a broad
suite of intellectual property, and some of the most
respected minds in this dynamic field. There are three
strategic components to Arrowhead's business model:
-- The Commercialization Program: Arrowhead forms
or acquires majority-owned subsidiary companies pursuing
products based on nanotechnology in high-growth technology
markets.
-- The Research Program: Arrowhead funds nanoscience
research at universities in exchange for exclusive
rights to license the technology.
-- The Patent Toolbox: Arrowhead acquires, licenses,
and sublicenses intellectual property in nanotechnology.
Arrowhead Research operates four majority-owned subsidiary
companies:
-- Aonex Technologies, Inc., developing and commercializing
proprietary semiconductor nanomaterial technology.
-- Insert Therapeutics, Inc., developing and commercializing
a proprietary nanoscale drug delivery system.
-- Nanotechnica, Inc., developing capabilities for
mass-production of a variety of proprietary nanoscale
devices, including laboratory on a chip.
-- Calando Pharmaceuticals, Inc. is developing nanostructures
for delivery and therapeutic use of RNA interference.
Arrowhead is funding three research and development
efforts in nanotechnology at the California Institute
of Technology.
Contacts
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549
bruce@arrowres.com
